Siren Biotechnology today announced the publication of its first peer-reviewed manuscript in Molecular Therapy Oncology, ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present k ...
Oral presentation highlights novel compact RT editor demonstrating first preclinical in vivo proof of concept for precise ...
IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month ...
PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...
Dr. Ronald Crystal is a founder, chief scientific advisor, consultant, equity holder and board observer of Lexeo Therapeutics and is an inventor on intellectual property assigned to Weill Cornell ...
The MarketWatch News Department was not involved in the creation of this content. HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted ...
CDMO Andelyn Biosciences partnered with Amplo Biotechnology, which focuses on adeno-associated virus (AAV) regenerative medicines for neuromuscular junction-(NMJ) affecting conditions, to provide ...
Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
Circio Holding announces, it is presenting new and confirmatory in vivo data for its circVec-AAV expression platform. The in vivo results show, for the first time, up to 50-fold enhanced AAV-circVec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results